Videos

The expert faculty review the pivotal phase 3 CREST trial, which evaluated subcutaneous sasanlimab in combination with Bacillus Calmette–Guérin (BCG) for BCG-naïve, high-risk non–muscle invasive bladder cancer (NMIBC).

Fed Ghali, MD, discusses the potential opportunity to de-escalate therapy in patients receiving perioperative EV/pembro.

Gal Wald, MD, highlights patient-reported outcomes from a phase 2 trial of intravesical gemcitabine plus BCG for patients with BCG-exposed high-grade NMIBC.

Explore the complexities of treating mCRPC with personalized immunotherapies, addressing comorbidities and patient response challenges.

Healthcare professionals discuss adapting treatment guidelines based on genomic testing, emphasizing early detection and personalized care for high-risk patients.

Another critical research need involves understanding the effects of exogenous testosterone.

Sameena A. Rahman, MD, said she anticipates that the regulatory stance may encourage more clinicians to adopt a layered therapeutic approach for patients with severe GSM.

Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus.

Eugene Pietzak, MD, highlights the background and design of the ongoing phase 3 GAIN trial, exploring the combination of gemcitabine and BCG in BCG-exposed NMIBC.

The primary end point is overall survival, with secondary end points including PSA response metrics, progression measures, PSA kinetics, and several ctDNA assessments to help identify which patients benefit most.

Arvin K. George, MD, discusses the unique design of the VAPOR 2 trial and the key findings from the first 110 patients enrolled.

Siamak Daneshmand, MD, emphasizes that, at present, optimal patient selection remains unclear because resistance mechanisms and predictive biomarkers are not yet well understood.

Explore the evolving landscape of prostate cancer treatments, focusing on efficacy, tolerability, and the nuances of various therapies.

Experts discuss the future of metastatic cancer treatment, focusing on risk stratification, personalized therapies, and the balance between intensification and de-escalation.

Mark D. Tyson, II, MD, MPH, recapped topline results from the BOND-003 trial of cretostimogene grenadenorepvec in papillary only BCG-unresponsive NMIBC.

For patients undergoing salvage surgery or radiation, Kelly L. Stratton, MD, FACS, notes that previous focal therapy can influence outcomes.

TULSA patients were treated and discharged the same day.

Laura Bukavina, MD, MPH, offered her thoughts on the significance of the KEYNOTE-905 data and highlighted some remaining questions surrounding the regimen.

Stratton emphasized that the trial’s results provide greater confidence in recommending therapy and allow clinicians to counsel patients more decisively about next steps when PSA begins to rise.

Michael S. Cookson, MD, MMHC, FACS, shares his thoughts on the most exciting recent advances in bladder cancer treatment.

Joshua J. Meeks, MD, PhD, discussed the emerging role of ctDNA in guiding adjuvant and neoadjuvant strategies in patients with bladder cancer.

Laser technology is expected to play a major role in the next wave of innovation.

Learn how suction has become central to contemporary ureteroscopic practice and how its integration is reshaping surgical decision-making, treatment algorithms, and the perceived role of percutaneous procedures.

Karen L. Stern, MD, and Naeem Bhojani, MD, FRCSC, outline the advantages of CVAC 2.0, particularly in cases involving larger stone burdens.

Experts compare and contrast direct in-scope suction with the flexible and navigable ureteric access sheath.

In this opening segment, the discussion focuses on the rapid evolution of kidney stone surgery and how suction has transitioned from an aspirational idea to a core component of modern ureteroscopy.

Panelists discuss how proactive education, regular follow-up, and multidisciplinary support improve adherence to oral ARPI therapy and drive better real-world outcomes in mCSPC.

The expert faculty analyze the recently presented ALBAN trial, a phase 3 study evaluating atezolizumab in combination with intravesical BCG versus BCG alone for BCG-naïve, high-risk non–muscle invasive bladder cancer (NMIBC).

Cameron J. Britton, MD, highlights key findings from a study of the MyProstateScore 2.0 in predicting upgrading to GG≥3 prostate cancer.